HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Safe Level For CBD As Dietary Ingredient? FDA Continues Data Review

Executive Summary

Associate commissioner Lowell Schiller's comments at recent trade group regulatory conference mark agency's first public statement on likely direction on CBD's use in food, supplements. Potentially allowing CBD's use also is making FDA "think about whether we have the tools and resources we need to take this on," Schiller said.

You may also be interested in...



US Wellness Market In 2019: Farm Bill Made Cultivating Cannabidiol Policy FDA's Main Course In Supplements

As HBW Insight looks back on notable US wellness market developments and events for the previous 12 months, we find that news in the CBD space from the FDA and the industry dominated the sector throughout 2019.

FDA Unfairly ‘Maligning’ Responsible CBD Product Marketers – Council For Responsible Nutrition

Dietary supplement trade groups reacted on 26 November – in CRN’s case with umbrage – to the US Food and Drug Administration’s latest barrage of cannabidiol (CBD)-themed warning letters and accompanying update to consumers regarding CBD safety.

FDA Suggests Legislation To Streamline Enforcement In Supplement Market

Congress should consider legislation authorizing agency to conduct enforcement more directly, says Associate Commissioner Schiller. In FDLI conference keynote, he discussed compliance with FDA regulations across markets it regulates, but made specific example of saying FDA is comparatively hamstrung in regulating businesses marketing products labeled as supplements.

Related Content

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel